Pluri (PLUR)
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies f...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Pluri Analyst Rating
View moreForecast & Rating
Jun 2, 2025Price forecast
$12.001088.12%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Sep 18 at 12:06 PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
- TradingView · Sep 10 at 09:25 PM
Pluri Inc. FY 2026: Revenue $1.02M, EPS $(2.44) — 10-K Summary
- PUBT · Sep 10 at 09:20 PM
Pluri FY26 net loss widens to $25.37 million; revenue falls to $1.02 million
- Simplywall · Sep 2 at 12:20 PM
Insiders' US$14.6m Investments In Red Following Pluri's US$2.2m Dip In Market Value
- PUBT · Aug 28 at 11:35 AM
Pluri prices registered direct offering at $1.5 per share, targets $2.98 million net proceeds
